US Broker Ratings

Cogent Biosciences, Inc. (COGT) Stock Analysis: Exploring a Potential 43% Upside with Innovative Biotech Approaches

Cogent Biosciences, Inc. (NASDAQ: COGT) is capturing investor attention with its innovative approach to precision therapies and a promising potential upside of 43.20%. This biotechnology company, headquartered in Waltham, Massachusetts,..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Exploring a 46% Potential Upside Amid Diagnostic and Therapeutic Growth

Fulgent Genetics, Inc. (NASDAQ: FLGT), a key player in the healthcare sector, offers a compelling investment opportunity with a significant potential upside of 46.57%. As a prominent entity in the..

OrthoPediatrics Corp. (KIDS) Stock Analysis: Exploring a 43.54% Potential Upside in the Pediatric Medical Device Market

OrthoPediatrics Corp. (NASDAQ: KIDS) is carving a niche in the healthcare sector, specifically within the medical devices industry, by focusing on the unique orthopedic needs of children. With a market..

Akso Health Group (AHG) Stock Analysis: Navigating the Complexities of a Challenging Market

For investors searching for opportunities within the healthcare sector, Akso Health Group (AHG) presents a fascinating case study. With a market capitalization of $1.23 billion, this China-based company operates in..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Potential Upside of Over 210% Draws Investor Attention

Niagen Bioscience, Inc. (NAGE), a promising player in the biotechnology sector, is capturing investor interest with its significant growth potential. With a market capitalization of $406.21 million, Niagen is strategically..

Nuvation Bio Inc. (NUVB) Stock Analysis: Unveiling a 105% Potential Upside in Biotech Innovation

For investors seeking opportunities in the burgeoning field of biotechnology, Nuvation Bio Inc. (NUVB) stands out with a compelling narrative. Based in New York, this clinical-stage biopharmaceutical company specializes in..

AbCellera Biologics Inc. (ABCL) Stock Analysis: A Biotech with a 234% Potential Upside

Investors with an appetite for high-risk, high-reward opportunities may find AbCellera Biologics Inc. (NASDAQ: ABCL) an intriguing prospect. This Vancouver-based biotechnology company has captured attention with its innovative approach to..

Pharvaris N.V. (PHVS) Stock Analysis: Potential Upside of 75% in the Biotech Sector

Pharvaris N.V. (PHVS), a Switzerland-based biotech firm, is generating buzz in the healthcare sector with its promising pipeline focused on rare diseases. With a market capitalization of $1.73 billion, the..

Xeris Biopharma Holdings (XERS) Investor Outlook: Aiming for a 61% Upside with Strong Buy Ratings

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is garnering significant attention in the biotechnology sector with its promising pipeline of therapies aimed at chronic endocrine and neurological diseases. This Chicago-based biopharmaceutical..

Day One Biopharmaceuticals, Inc. (DAWN): Analyst Ratings Suggest 110% Upside Potential

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN), a rising player in the biotechnology sector, is drawing significant attention from investors thanks to a promising pipeline of treatments and a striking 110.23%..

Iovance Biotherapeutics, Inc. (IOVA): A 261% Potential Upside Sparks Investor Interest

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is capturing the attention of the biotechnology investment community with its intriguing blend of innovative treatments and a substantial potential upside. With a current market..

Avadel Pharmaceuticals plc (AVDL) Stock Analysis: Navigating a 55% Revenue Surge with Caution

Exploring the dynamic realm of specialty and generic drug manufacturing, Avadel Pharmaceuticals plc (NASDAQ: AVDL) stands out with its significant market presence and compelling financial story. Headquartered in Dublin, Ireland,..

Maravai LifeSciences Holdings (MRVI): Analyst Consensus and Growth Potential Amid Challenging Metrics

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a prominent player in the biotechnology sector, has been a focal point for investors intrigued by its role in the life sciences industry. With..

Spyre Therapeutics, Inc. (SYRE) Stock Analysis: A Promising 62.78% Upside in Biotech Innovations

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a dynamic player in the biotechnology sector, is capturing investor attention with its promising pipeline in the treatment of inflammatory bowel disease (IBD). As a..

Savara, Inc. (SVRA) Stock Analysis: Exploring an 85% Potential Upside in the Biotech Sector

Savara, Inc. (NASDAQ: SVRA) is gaining attention in the biotechnology sector, thanks to its focus on addressing rare respiratory diseases. With a market capitalization of $1.19 billion, this clinical-stage biopharmaceutical..

SI-BONE, Inc. (SIBN) Stock Analysis: A 69.56% Potential Upside Amid Strong Buy Ratings

SI-BONE, Inc. (NASDAQ: SIBN), a healthcare industry contender specializing in medical devices, presents an intriguing opportunity for investors eyeing the growing field of musculoskeletal disorder treatments. The company, with a..

CeriBell, Inc. (CBLL) Stock Analysis: A 41% Upside Potential in Revolutionary Medical Devices

CeriBell, Inc. (CBLL) is a burgeoning name within the healthcare sector, specifically in the medical devices industry, and is making waves with its innovative approach to neurological diagnostics. Headquartered in..

Simulations Plus, Inc. (SLP) Stock Analysis: Exploring a 103% Potential Upside in Health Information Services

Simulations Plus, Inc. (SLP), a prominent player in the healthcare sector, has emerged as a compelling choice for investors seeking potential growth in the Health Information Services industry. Specializing in..

GH Research PLC (GHRS) Stock Analysis: Potential Upside of 124.74% and Strong Buy Ratings

Investors seeking opportunities in the healthcare sector should pay attention to GH Research PLC (NASDAQ: GHRS), a promising player in the biotechnology industry. Based in Dublin, Ireland, GH Research is..

uniQure N.V. (QURE) Stock Report: Exploring a 138% Potential Upside in the Biotech Arena

For investors with an eye on the biopharmaceutical sector, uniQure N.V. (NASDAQ: QURE) presents a compelling opportunity, marked by a significant potential upside of 138.58%. This Dutch-based biotechnology company, specializing..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds